Affy to Provide LabCorp With Chips for Cyto Service; Will Launch Catalog DMET in H2

Both the LabCorp deal and the roll-out of DMET could help to build Affy’s presence in the clinical testing and pharmacogenomics markets at a time when the bulk of its annual revenues come from the research community as opposed to biotechs and pharmas.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.

Related Stories